FMR1 and fragile X syndrome: Consistent with these proposed mechanisms of action of cannabidiol in FXS, the transdermal cannabidiol gel, ZYN002, was associated with improvements in measures of social avoidance, irritability, and social interaction in the CONNECT-FX trial, particularly among patients with ≥90% methylation of the FMR1 gene.